Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD147 chimeric antigen receptor-natural killer Cell Therapy - Protheragen

Drug Profile

Anti-CD147 chimeric antigen receptor-natural killer Cell Therapy - Protheragen

Alternative Names: CD147-CAR-NK

Latest Information Update: 11 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protheragen
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Liver cancer

Highest Development Phases

  • Preclinical Liver cancer

Most Recent Events

  • 11 Oct 2021 Anti-CD147 chimeric antigen receptor-natural killer Cell Therapy - Protheragen is available for licensing as of 11 Oct 2021. https://www.protheragen.com/available-projects/off-the-shelf-anti-cd147-car-nk-cell-therapy-for-hepatocellular-carcinoma/
  • 11 Oct 2021 Protheragen announces intention to submit IND to for Liver cancer (Protheragen pipeline, October 2021)
  • 07 Oct 2021 Preclinical trials in Liver cancer in USA (Parenteral) before October 2021 (Protheragen's pipeline, October 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top